APP and Alzheimer disease: In addition to these promising data, BIIB042 did not inhibit Notch signaling in an in vitro model.207 In a more advanced study conducted on human APP-overexpressing Tg2576 mice, BIIB042 reduced the levels of Aβ42 and decreased the amyloid plaque burden.208 BIIB042 is a candidate drug for AD.209